Laboratory Services
VacTimmune Vaccine Development
Revolutionising the Approach to Treating Infectious Diseases
The AMR Challenge
The World Health Organisation (WHO) has identified certain antimicrobial-resistant organisms as critical threats to global health. These pathogens are fast becoming untreatable with conventional antibiotics, making them a clear and present danger. At VacTimmune, we’ve taken up the challenge to combat these AMR organisms head-on. Our research and development efforts are specifically targeted at creating vaccines to counteract these critical threats.
Addressing AMR: VacTimmune tackles the growing challenge of antimicrobial resistance (AMR) through innovative vaccine development.
Revolutionising Prevention: Focused on preventing infectious diseases with cutting-edge solutions.
Rapid Vaccine Discovery: Utilizes an accelerated reverse vaccine discovery pipeline with advanced in silico and in vitro techniques.
Rigorous Testing: Ensures effectiveness with thorough testing in relevant in vivo models.
Our Advantages
The VacTimmune Vision
Our vision is simple but profound: a world where bacterial infections are no longer a formidable threat to human health. We’re committed to developing vaccines that can protect us from the ever-evolving world of infectious diseases and the alarming rise of AMR organisms.
8+
Vaccines in development
5
Awards Earned
Vaccine Development
Our Approach to Accelerated Vaccine Discovery
01
Efficiency
Pipeline Development
Our pipeline uses a unique combination of advanced computational methods and in vitro screening to identify promising vaccine candidates swiftly.
02
Validation
Rigorous Testing
To ensure the effectiveness of our vaccine candidates, we subject them to rigorous in vivo testing, simulating real-world infection scenarios.
03
Collaboration
Scientific Discovery
We collaborate with leading experts in microbiology, immunology, and bioinformatics to stay at the forefront of scientific discovery.
Vaccines in Development
We are actively working on several vaccines, currently in pre-clinical development, targeting a range of antibiotic-resistant bacteria and related health concerns:
- Pseudomonas aeruginosa
- Klebsiella pneumoniae
- Enterobacter cloacae complex
- Staphylococcus aureus
- Streptococcus
- Escherichia coli
- Neonatal sepsis
- Sexual health
OUr team
Vaccine Pioneers
Dr Paulina Zarodkiewicz
CSO
Dr Paulina Zarodkiewicz is a microbiologist with expertise in molecular biology and vaccine development against bacterial pathogens. She earned her B.A. (Mod.) in Microbiology from Trinity College Dublin and an M.Sc. in Molecular Biology and Biotechnology from Queen’s University Belfast. Her PhD, part of the Marie Sklodowska-Curie Actions ITN Bactivax, focused on identifying vaccine candidates for Gram-negative bacteria. Dr Zarodkiewicz conducted her research at the Wellcome-Wolfson Institute for Experimental Medicine in Queen’s University Belfast under Prof Valvano and Dr Ingram.
Dr Beckie Ingram
CEO
Dr Beckie Ingram is a T-cell immunologist, with a track record in vaccine antigen discovery and characterisation of the immune response to bacterial pathogens. She has worked extensively on organisms with the potential for bioterrorism and developed the vaccine pipeline the company utilises. She also has extensive expertise with preclinical infection models She is a member of the UK BactiVac network and a PI of the All-Island Vaccine Research and Training Network (AIVRT) recently funded by an HEA North-South award to develop vaccines to prevent AMR respiratory pathogens.
Miguel Valvano
Member of Board of Directors
Prof. Miguel Valvano has established an internationally recognised research programme focused on lipopolysaccharide (LPS) biogenesis and the molecular pathogenesis of opportunistic bacteria. His pioneering research has advanced understanding of conserved biological processes, particularly in LPS O-antigen assembly and protein glycosylation in bacterial systems. Prof. Valvano’s work has significantly contributed to knowledge of the molecular basis of intrinsic antimicrobial resistance, offering vital insights into bacterial survival mechanisms.
Join the fight against infectious diseases!
The battle against bacterial infections and antimicrobial resistance is a formidable one, but with your support and our innovative approach to vaccine development, we believe that we can turn the tide. Together, we can build a safer, healthier future for generations to come.
Contact us today to learn more about our research, our team, and our vision. Together, we can create a world where bacterial infections are no longer a looming threat.